Insomnia entails a spectrum of complaints reflecting dissatisfaction with the quality, duration, or continuity of sleep. These complaints may involve problems with falling asleep initially at bedtime (initial insomnia), waking up in the middle of the night and having difficulty going back to sleep (middle insomnia), waking up too early in the morning with an inability to sleep until planned rise time (late insomnia), or a perception of non restorative sleep. Insomnia may be transient, episodic, or persistent over time (Morin & Espie, 2003). Approximately one third of the adult population reports insomnia symptoms, whereas about 10% suffer from an insomnia disorder (Ohayon, 2002).
Along with subjective complaints of poor sleep, individuals with insomnia are often distressed about their sleep and also report significant fatigue and impairments of their daytime functioning. Common sleep-loss related daytime problems include difficulties with attention, concentration, memory, and completion of tasks, and negative mood. Chronic insomnia is also associated with reduced quality of life, decreased productivity, increased absenteeism from work, and increased risk for depression.
Primary vs. coexisting insomnia
Insomnia may be a primary sleep disorder or it may manifest itself as a co-occurring condition with another psychiatric, medical, or another sleep disorder (National Institutes of Health; NIH , 2005). The International Classification of Sleep Disorders recognizes at least three different subtypes of primary insomnia: psychophysiological, paradoxical, and idiopathic insomnia (American Academy of Sleep Medicine, 2005; AASM).- Psychophysiological insomnia is the most classic form of insomnia and is the result from the repeated pairings of situational (bed/bedroom) and temporal (bedtime) stimuli, normally associated with sleep, with conditioned cognitive, emotional and/or physiologic arousal.
- Paradoxical insomnia involves a genuine complaint of little or no sleep that is not corroborated by objective evidence of sleep disturbances.
- Idiopathic insomnia presents an insidious onset during childhood, unrelated to psychosocial stressors or medical disorders, and is very persistent throughout the adult life.
The biological basis of insomnia
Biological factors contributing to insomnia include homeostatic and circadian regulation of the sleep-wake system (Pigeon & Perlis, 2006). Hyperarousal is also considered a central feature of insomnia (Bonnet & Arand, 1996). Physiological markers of hyperarousal include increased heart rate, body temperature, metabolic rate, and cortisol levels. These markers may be state-related and conditioned to sleep-related stimuli or they may reflect a more enduring trait feature present throughout the 24-hour period. There is also evidence of increased cortical arousal in insomnia, as evidenced by higher quantity of fast EEG brain waves (alpha, beta) relative to the lower EEG frequency bands (delta, theta) among individuals with insomnia relative to good sleepers. This increased cortical arousal is consistent with the hypervigilance and racing mind that often characterized insomnia. It is likely that both biological and psychological factors contribute to increase arousal and to interfere with normal initiation and maintenance of sleep.The role of psychological factors and life events
Psychological and behavioral factors also play an important role in the development and maintenance of insomnia as evidenced by higher levels of pre-sleep cognitive arousal (e.g., intrusive thoughts, worries) and general psychological reactivity among individuals with insomnia relative to good sleepers. Insomniacs also tend to present an anxiety-prone personality style that may predispose them to worry more about sleep. Life events contribute to trigger insomnia, but it is often the reduced ability to cope with daily stressors, combined with increased cognitive arousal at bedtime, that leads to sleep disturbances (Morin & Espie, 2003). Learning and conditioning are also involved in the maintenance or exacerbation of sleep disturbances. Potential risk factors for insomnia include female gender, advancing age, a worry-prone cognitive style, hyperarousal, and a past history of insomnia. For most individuals, insomnia is transient in nature, lasting a few days, and resolving itself once the initial precipitating event has subsided. For others, insomnia may persist long after the initial triggering event has disappeared; other factors would then perpetuate sleep disturbances. The course of insomnia may also be intermittent, with repeated brief episodes of sleep difficulties following a close association with the occurrence of stressful events.Spielman’s 3P Model of Insomnia
Three types of factors are involved at different points during the course of insomnia.- Predisposing factors: Some psychological or biological characteristics increase vulnerability, or predisposition, to sleep difficulties (e.g., female gender, anxiety, hyperarousal). These factors are not a direct cause of insomnia, but they increase the risk that an individual will develop sleep difficulties.
- Precipitating factors: These are the life events and the medical, environmental or psychological factors that trigger insomnia (e.g., divorce, death of a significant other, illness, medication, familial or occupational stress).
- Perpetuating factors: These elements maintain or exacerbate sleep difficulties. They are typically behaviors (e.g., extending time spend in bed to try to sleep more, naps) and/or beliefs and thoughts (fear of sleeplessness, excessive worries about daytime consequences) that people adopt in order to cope with sleeplessness. Although some of these behaviors (bed resting) can be useful in the short term, in the long run they have the opposite effect and tend to perpetuate insomnia.
Treatment options
The first step in treating symptomatic insomnia is to identify and remove contributing factors to the sleep problems. General sleep hygiene recommendations are also useful as preventative strategies. Insomnia-specific therapies include psychological and behavioral interventions, medications, and a variety of complementary and alternative therapies (e.g., dietary and herbal supplements).Psychological and behavioral interventions
The main objective of psychological and behavioral approaches is to alter those factors that perpetuate or exacerbate sleep disturbances.- Sleep restriction consists of curtailing the amount of time spent in bed to the actual amount of sleep. This procedure targets reducing unwanted wake time and leads to improvements of sleep continuity through a mild sleep deprivation.
- Stimulus control therapy consists of a set of instructions designed to re-associate temporal (bedtime) and environmental (bed and bedroom) stimuli with rapid sleep onset and to establish a regular circadian sleep-wake rhythm.
- Relaxation-based interventions such as progressive-muscle relaxation aim at reducing somatic arousal (e.g., muscle tension), whereas attention-focusing procedures (e.g., imagery training, meditation) target sleep-interfering mental arousal in the forms of worries, intrusive thoughts, or a racing mind.
- Cognitive therapy is a psychotherapeutic method that seeks to alter dysfunctional sleep cognitions (e.g., beliefs, expectations, attributions) and maladaptive cognitive processes (e.g., excessive self-monitoring or worrying) in order to reduce distress, improve coping and facilitate sleep.
- Sleep hygiene education is intended to provide information about lifestyle, habits (diet, exercise, and caffeine, alcohol, tobacco, over-the counter and prescribed drug use) and environmental factors (light, noise, temperature) that may interfere with sleep as well as those that promote better sleep.
Prescribed medications
Medication (prescribed and over-the-counter) is the most common treatment used for insomnia. Only two classes of medications, benzodiazepine-receptor agonists (BRA) and melatonin-receptor agonists, are approved by the Food and Drug Administration of the United States of America for the treatment of insomnia. BRA include the traditional benzodiazepines (e.g., flurazepam, temazepam), and the more recent non-benzodiazepine receptor agonists (e.g., zolpidem, eszopiclone, zaleplon). The most recent hypnotic introduced on the market, ramelteon, is a melatonin-receptor agonist. These agents have all been found effective for the short-term treatment of insomnia. Despite a relative lack of data and no government-approved indication for insomnia, sedating antidepressants, such as the tricyclics, trazodone and mirtazapine, are commonly prescribed agents for treating chronic insomnia. There is relatively little efficacy data regarding the use of these agents specifically for insomnia (NIH, 2005). Overall, pharmacotherapy is a useful therapeutic option to alleviate transient insomnia. The role of long-term use of hypnotics, however, is controversial and there is limited evidence at this time to support this clinical practice. Behavioral approaches, alone or combined with brief pharmacotherapy, should be preferred to continuous long-term use of hypnotics to treat chronic insomnia.Herbal and Dietary Supplements
An increasing number of natural (herbal/dietary) products are marketed as sleep aids. Such products include melatonin, valerian roots (valeriana officinalis), passionflower, chamomille, and L-Tryptophan. Despite their popularity and widespread use, there is currently not enough evidence to recommend the use of any herbal and dietary supplements for the management of clinical insomnia. In addition, there are always risks associated with products that are not monitored by government-regulated health agencies. In summary, insomnia is a prevalent public health problem that may be associated with negative psychosocial, economic and health outcomes. Several treatment options are available but the only two interventions that are currently supported by scientific evidence are cognitive behavioral therapy and the benzodiazepine-receptor agonists (NIH, 2005).References
- American Academy of Sleep Medicine. (2005). International classification of sleep disorders: Diagnostic and coding manual (2nd ed.). Westchester, IL: American Academy of Sleep Medicine.
- Bonnet M, Arand D. (1997). Hyperarousal and insomnia. Sleep Medicine Reviews 2:97-108.
- Breslau N, Roth T, Rosenthal L, Andreski P. (1996). Sleep disturbance and psychiatric disorders: A longitudinal epidemiological study of young adults. Biological Psychiatry 39:411-418.
- Ford DE, Kamerow DB. (1989). Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? Journal of the American Medical Association 262:1479-1484.
- Morin CM, Espie CA (2003). Insomnia: A clinical guide to assessment and treatment. New York: Kluwer Academic/Plenum Publishers.
- Morin CM, Bootzin RR, Buysse DJ, Edinger JD, Espie CA, Lickstein KL. (2006). Psychological and behavioral treatment of insomnia: Update of the recent evidence (1998-2004). Sleep 29:1398-1414.
- National Institutes of Health (2005). National Institutes of Health state of the science conference statement on manifestations and management of chronic insomnia in adults. Sleep 28:1049-1057.
- Ohayon MM. (2002). Epidemiology of insomnia : What we know and what we still need to learn. Sleep Medicine Reviews 6:97-111.
- Pigeon W. & Perlis M. (2006). Sleep homeostasis in primary insomnia. Sleep Med Reviews, 10, 247-254.
- Spielman AJ, Glovinsky P. (1991). The varied nature of insomnia. In PJ Hauri (Ed.). Case studies in insomnia. New York, Plenum Press.
Suggested websites
- The National Sleep Foundation (http://www.sleepfoundation.org/)
- Centers of Disease Control and Prevention (http://www.cdc.gov/sleep/)
- American Academy of Sleep Medicine (http://aasmnet.org/)